Basic Information
TEZSPIRE SOLUTION FOR INJECTION 210 MG IN PRE-FILLED SYRINGE
INJECTION, SOLUTION
Regulatory Information
SIN16815P
July 4, 2023
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
May 30, 2025
XR03DX11
Company Information
Active Ingredients
Strength: 210 mg/unit
Detailed Information
Contraindications
**4.3 Contraindications** TEZSPIRE is contraindicated in patients who have known hypersensitivity to tezepelumab or any of its excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** TEZSPIRE is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite medium or high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.